Yusuke Miyazaki

1.5k total citations
60 papers, 993 citations indexed

About

Yusuke Miyazaki is a scholar working on Rheumatology, Immunology and Pathology and Forensic Medicine. According to data from OpenAlex, Yusuke Miyazaki has authored 60 papers receiving a total of 993 indexed citations (citations by other indexed papers that have themselves been cited), including 43 papers in Rheumatology, 30 papers in Immunology and 12 papers in Pathology and Forensic Medicine. Recurrent topics in Yusuke Miyazaki's work include Systemic Lupus Erythematosus Research (24 papers), Rheumatoid Arthritis Research and Therapies (14 papers) and Autoimmune and Inflammatory Disorders Research (8 papers). Yusuke Miyazaki is often cited by papers focused on Systemic Lupus Erythematosus Research (24 papers), Rheumatoid Arthritis Research and Therapies (14 papers) and Autoimmune and Inflammatory Disorders Research (8 papers). Yusuke Miyazaki collaborates with scholars based in Japan, China and Kazakhstan. Yusuke Miyazaki's co-authors include Shingo Nakayamada, Satoshi Kubo, Yoshiya Tanaka, Kazuhisa Nakano, S. Iwata, Ippei Miyagawa, Kei Sakata, Maiko Yoshikawa, Kazuyoshi Saito and Kentaro Hanami and has published in prestigious journals such as The Journal of Immunology, Frontiers in Immunology and Annals of the Rheumatic Diseases.

In The Last Decade

Yusuke Miyazaki

56 papers receiving 985 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Yusuke Miyazaki Japan	16	628	554	119	106	102	60	993
Laura Nuño Spain	16	562 0.9×	478 0.9×	117 1.0×	159 1.5×	209 2.0×	60	944
Amalia Raptopoulou Greece	12	444 0.7×	540 1.0×	80 0.7×	98 0.9×	89 0.9×	16	979
María‐Eugenia Miranda‐Carús Spain	17	465 0.7×	529 1.0×	118 1.0×	51 0.5×	120 1.2×	30	1.0k
A. Nzeusseu Toukap Belgium	14	549 0.9×	226 0.4×	144 1.2×	56 0.5×	83 0.8×	36	784
Taro Iwamoto Japan	13	513 0.8×	323 0.6×	85 0.7×	125 1.2×	40 0.4×	41	933
Aase Hensvold Sweden	19	747 1.2×	344 0.6×	114 1.0×	84 0.8×	315 3.1×	49	1.2k
Stefania Sacco Italy	13	502 0.8×	264 0.5×	176 1.5×	155 1.5×	144 1.4×	20	958
Norifumi Sawamukai Japan	14	359 0.6×	267 0.5×	134 1.1×	58 0.5×	65 0.6×	25	672
B. Combe France	13	638 1.0×	301 0.5×	247 2.1×	55 0.5×	87 0.9×	22	959
Ana Malvar Argentina	16	1.3k 2.1×	753 1.4×	69 0.6×	87 0.8×	397 3.9×	45	1.6k

Countries citing papers authored by Yusuke Miyazaki

Since Specialization

Citations

This map shows the geographic impact of Yusuke Miyazaki's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yusuke Miyazaki with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yusuke Miyazaki more than expected).

Fields of papers citing papers by Yusuke Miyazaki

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yusuke Miyazaki. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yusuke Miyazaki. The network helps show where Yusuke Miyazaki may publish in the future.

Co-authorship network of co-authors of Yusuke Miyazaki

This figure shows the co-authorship network connecting the top 25 collaborators of Yusuke Miyazaki. A scholar is included among the top collaborators of Yusuke Miyazaki based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yusuke Miyazaki. Yusuke Miyazaki is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Nakayamada, Shingo, Satoshi Kubo, Yusuke Miyazaki, et al.. (2025). Association of peripheral CD8⁺ T cell activation with disease activity and treatment resistance in systemic lupus erythematosus. RMD Open. 11(1). e005122–e005122. 1 indexed citations

Miyazaki, Yusuke, Yuya Fujita, Masanobu Ueno, et al.. (2025). Transition of clinical remission rates with molecular targeted therapies in rheumatoid arthritis in Japan: insights from the FIRST registry. Lara D. Veeken. 64(9). 5023–5030. 1 indexed citations

Miyazaki, Yusuke, Shingo Nakayamada, Shunsuke Fukuyo, et al.. (2025). Effective Second-Line b/tsDMARDs for Patients with Rheumatoid Arthritis Unresponsive to First-Line b/tsDMARDs from the FIRST Registry. Rheumatology and Therapy. 12(2). 353–369. 2 indexed citations

Kobayashi, Hiroki, Yusuke Miyazaki, Shingo Nakayamada, et al.. (2024). Predictors of the effectiveness of first-line CTLA4-Ig in patients with RA: the FIRST registry. Lara D. Veeken. 64(5). 2403–2410. 1 indexed citations

Sakai, H., Yusuke Miyazaki, Shingo Nakayamada, et al.. (2024). Efficacy, safety and optimal intervention of belimumab for proliferative lupus nephritis patients in real-world settings: LOOPS registry. Lara D. Veeken. 64(4). 1930–1939. 1 indexed citations

Iwata, S., Kaoru Yamagata, Yasuyuki Todoroki, et al.. (2024). Induction of interleukin 21 receptor expression via enhanced intracellular metabolism in B cells and its relevance to the disease activity in systemic lupus erythematosus. RMD Open. 10(4). e004567–e004567. 1 indexed citations

Kubo, Satoshi, Yusuke Miyazaki, T Nishino, et al.. (2024). Peripheral blood immunophenotypic diversity in patients with rheumatoid arthritis and its impact on therapeutic responsiveness. Annals of the Rheumatic Diseases. 84(2). 210–220. 8 indexed citations

Miyazaki, Yusuke, Shingo Nakayamada, Koshiro Sonomoto, et al.. (2023). Safety and efficacy of anifrolumab therapy in systemic lupus erythematosus in real-world clinical practice: LOOPS registry. Lara D. Veeken. 63(9). 2345–2354. 8 indexed citations

Tanaka, Hiroaki, Yukinori Okada, Shingo Nakayamada, et al.. (2023). Extracting immunological and clinical heterogeneity across autoimmune rheumatic diseases by cohort-wide immunophenotyping. Annals of the Rheumatic Diseases. 83(2). 242–252. 9 indexed citations

10.

Nawata, Aya, Shingo Nakayamada, Satoshi Hisano, et al.. (2023). Differential expression of IFN-α, IL-12 and BAFF on renal immune cells and its relevance to disease activity and treatment responsiveness in patients with proliferative lupus nephritis. Lupus Science & Medicine. 10(2). e000962–e000962. 8 indexed citations

11.

Iwata, S., Shinsuke Hidese, Sayuri Ishiwata, et al.. (2023). Reduced homovanillic acid, SDF-1α and SCGF-β levels in cerebrospinal fluid are related to depressive states in systemic lupus erythematosus. Lara D. Veeken. 62(10). 3490–3500. 3 indexed citations

12.

Ueno, Masanobu, Ippei Miyagawa, Koichi Kimura, et al.. (2022). Safety and effectiveness of mepolizumab therapy in remission induction therapy for eosinophilic granulomatosis with polyangiitis: a retrospective study. Arthritis Research & Therapy. 24(1). 159–159. 17 indexed citations

13.

Miyagawa, Ippei, Shingo Nakayamada, Masanobu Ueno, et al.. (2022). Precision medicine based on the phenotypic differences in peripheral T helper cells in patients with psoriatic arthritis: One year follow-up outcomes. Frontiers in Medicine. 9. 934937–934937. 5 indexed citations

14.

Miyagawa, Ippei, Shingo Nakayamada, Masanobu Ueno, et al.. (2022). Impact of serum interleukin-22 as a biomarker for the differential use of molecular targeted drugs in psoriatic arthritis: a retrospective study. Arthritis Research & Therapy. 24(1). 86–86. 9 indexed citations

15.

Ueno, Masanobu, Ippei Miyagawa, Kazuhisa Nakano, et al.. (2021). Effectiveness and safety of mepolizumab in combination with corticosteroids in patients with eosinophilic granulomatosis with polyangiitis. Arthritis Research & Therapy. 23(1). 86–86. 25 indexed citations

16.

Miyazaki, Yusuke, Kazuhisa Nakano, Shingo Nakayamada, et al.. (2021). Efficacy and safety of tofacitinib versus baricitinib in patients with rheumatoid arthritis in real clinical practice: analyses with propensity score-based inverse probability of treatment weighting. Annals of the Rheumatic Diseases. 80(9). 1130–1136. 43 indexed citations

17.

Miyagawa, Ippei, Kazuhisa Nakano, Shingo Nakayamada, et al.. (2020). The additive effects of hydroxychloroquine to maintenance therapy with standard of care in patients with systemic lupus erythematosus. International Journal of Rheumatic Diseases. 23(4). 549–558. 10 indexed citations

18.

Miyazaki, Yusuke, Shingo Nakayamada, Satoshi Kubo, et al.. (2020). Favorable efficacy of rituximab in ANCA-associated vasculitis patients with excessive B cell differentiation. Arthritis Research & Therapy. 22(1). 141–141. 12 indexed citations

19.

Miyazaki, Yusuke, Shingo Nakayamada, Satoshi Kubo, et al.. (2018). Th22 Cells Promote Osteoclast Differentiation via Production of IL-22 in Rheumatoid Arthritis. Frontiers in Immunology. 9. 2901–2901. 51 indexed citations

20.

Nakayamada, Shingo, Satoshi Kubo, Maiko Yoshikawa, et al.. (2017). Differential effects of biological DMARDs on peripheral immune cell phenotypes in patients with rheumatoid arthritis. Lara D. Veeken. 57(1). 164–174. 71 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact